Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health's SEC filings reveal the financial mechanics behind America's largest healthcare company, but the three-segment structure means key metrics are scattered across different sections. The 10-K annual report breaks down performance for Pharmacy and Consumer Wellness (retail), Health Care Benefits (Aetna), and Health Services (Caremark), each with distinct profitability profiles and growth drivers.
For investors tracking Aetna's insurance business, the medical benefit ratio (MBR) disclosed in quarterly 10-Q filings shows what percentage of premiums goes to paying claims versus retained as profit. Medicare Advantage membership and star ratings, also disclosed in filings, directly impact government bonus payments worth billions annually.
CVS Caremark's PBM segment reports pharmacy claims processed, generic dispensing rates, and client retention metrics. These disclosures help assess competitive positioning against Express Scripts and OptumRx in the concentrated PBM market.
The retail pharmacy segment discloses prescription volume, front-store sales trends, and store count changes. Pharmacy reimbursement pressure from PBMs (including competitors) appears in management discussion sections, explaining margin compression that affects the entire retail pharmacy industry.
Form 4 insider transactions track executive stock activity across CVS Health's leadership team. Given the company's size and position in healthcare policy debates, insider trading patterns draw attention from institutional investors and analysts.
8-K filings capture material events including major contract announcements, acquisition completions, and leadership changes. Our AI summaries identify the business impact of each filing, saving hours of document analysis for healthcare investors following this complex, multi-segment company.
CVS Health (CVS) director J. Scott Kirby reported the receipt of additional company stock. On 11/20/2025, he acquired 1,652 shares of CVS Health common stock at a price of $76.04 per share. This was issued as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, rather than a market purchase.
Following this transaction, Kirby beneficially owns 12,987 CVS Health common shares, held directly. The filing is made on Form 4 as he serves as a director of CVS Health and is required to report changes in his ownership of company equity.
CVS Health director equity activity: A CVS Health Corp director reported routine equity compensation on a Form 4 for 11/20/2025. The director acquired 591 shares of common stock at $76.04 per share, which were issued as payment of a semi-annual cash retainer under the company’s 2017 Incentive Compensation Plan.
The filing also shows an award of 1,775.3814 deferred stock units, representing deferral of a semi-annual retainer under the non-employee director compensation policy. After this transaction, the director holds 16,530.0615 deferred stock units, each convertible into one share of CVS common stock to be issued in the future as elected by the director.
CVS Health reported a Form 4 for a director reflecting routine equity compensation. On 11/20/2025, the director acquired 1,652.091 deferred stock units with each unit representing one share of CVS Health common stock. These units were issued for deferral of a semi-annual retainer under the company’s non-employee director compensation policy and were valued at the market price pursuant to the 2017 Incentive Compensation Plan. After this transaction, the director beneficially owned 40,053.5157 deferred stock units on a direct basis.
CVS Health Corp reported an insider equity transaction by a company director on a Form 4. On 11/20/2025, the director acquired 1,775 shares of CVS Health common stock, labeled as an acquisition, at a price of $76.04 per share. The filing explains that these shares were issued as payment of a semi-annual retainer at the market price under the company’s 2017 Incentive Compensation Plan, meaning they represent stock-based compensation rather than an open-market purchase. Following this transaction, the director directly owns 127,772 shares of CVS Health common stock.
CVS Health (CVS) reported a routine equity compensation transaction for a director. On 11/20/2025, a CVS director received 1,775 shares of common stock at a price of $76.04 per share. The shares were issued as payment of a semi-annual retainer under CVS Health's 2017 Incentive Compensation Plan, rather than a cash payment.
Following this grant, the director beneficially owns 13,659 shares of CVS Health common stock in direct ownership. This filing reflects standard board compensation in stock and does not describe any broader corporate or strategic change at CVS Health.
CVS Health (CVS) director Fernando Aguirre reported the receipt of company stock as part of his regular board compensation. On 11/20/2025, he acquired 1,800 shares of CVS Health common stock at a price of $76.04 per share. This stock was issued as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, meaning it represents routine director compensation rather than an open-market purchase. Following this grant, Aguirre beneficially owns 40,950 shares of CVS Health common stock, held directly.
CVS Health Corporation announced a governance change at the top of its leadership structure. On November 20, 2025, the Board appointed President and Chief Executive Officer J. David Joyner to also serve as Chair of the Board, effective January 1, 2026. After this change takes effect, Michael F. Mahoney will continue as Lead Independent Director, and Roger N. Farah, currently Executive Chair, will remain on the Board as a director. The company also issued a press release describing this appointment, which is filed as an exhibit.
CVS Health (CVS) reported a Q3 2025 net loss driven by a non-cash impairment. Total revenues rose to $102.871B from $95.428B a year ago, led by higher product sales and premiums. However, a $5.725B goodwill impairment and higher operating costs pushed operating income to a loss of $3.207B versus income of $832M last year. Net loss attributable to CVS Health was $3.975B (diluted EPS -$3.13), compared with net income of $87M (EPS $0.07) in Q3 2024.
Year to date, revenues reached $296.374B, while net income attributable to CVS Health was a loss of $1.175B (EPS -$0.93). The quarter included a $483M gain on the deconsolidation of a subsidiary and $632M of net investment income. Cash from operations for the first nine months was $7.249B, essentially flat year over year. On the balance sheet, cash and cash equivalents were $9.098B, goodwill declined to $85.478B, and total debt (short-term, current portion of long-term, and long-term) remained significant. As of October 22, 2025, shares outstanding were 1,269,432,485.
FAQ
What is the current stock price of Cvs Health (CVS)?
What is the market cap of Cvs Health (CVS)?
